Endometrial cancer is one of the most common gynecological malignancies, which is closely related to metabolic syndrome such as diabetes mellitus. In recent years, epidemiological studies have found that metformin has a positive effect on the prevention and treatment of endometrial cancer, and a large number of basic and clinical studies have supported this theory, indicating that metformin may become the new treatment for patients with endometrial cancer, especially with advanced and recurrent endometrial cancer, and endometrial dysplasia.